All In Biotech

Drug Trial Radar · NCT02866825

Studying Complement Inhibition in Complex Cardiac Surgery

A Phase II Randomized, Placebo-controlled, Double-blind, Dose-escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamic Dose Response Relationship of IFX-1 in Patients Undergoing Complex Cardiac Surgery

Last checked: Nov 19, 2026Latest source record: Feb 15, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 116 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

116

Actual

Start

May 2016

Primary completion

Dec 2016

Study completion Jan 2017

Sponsor

Lead sponsor
InflaRx GmbHIndustry
Sponsor type
Industry
First posted
Aug 15, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial enrolls patients undergoing a complex cardiac surgery. The primary goal of the trial is to evaluate the pharmacodynamic dose response relationship of the monoclonal antibody IFX-1 in these patients. In addition, this trial further aims to characterize the safety and the pharmacokinetics of IFX-1 as well as to collect first data on its efficacy on clinical surrogate endpoints.

Conditions

  • Systemic Inflammatory Response Syndrome
  • C.Surgical Procedure; Cardiac

Interventions

  • IFX-1Biological

  • PlaceboBiological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak level of IL-6Time frame: From prior study drug administration until 24h after start of cardiopulmonary bypass (CPB) (CPB)

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Study Site

    Aachen, Germany

  • Study Site

    Dortmund, Germany

  • Study Site

    Dresden, Germany

  • Study Site

    Freiburg im Breisgau, Germany

  • Study Site

    Heidelberg, Germany

  • Study Site

    Jena, Germany

  • Study Site

    Kiel, Germany

  • Study Site

    Leipzig, Germany

  • Study Site

    Trier, Germany

  • Study Site

    Tübingen, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.